Search Results

Genetown

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, revealed significant growth in the CENTOGENE Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases.

May 10, 2024

·

6 min read

Genetown

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

CENTOGENE N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the voting results of the Company’s 2024 Annual General Meeting.

May 31, 2024

·

4 min read

Genetown

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

Centogene N.V. today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO).

May 14, 2024

·

9 min read

BioMidwest

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.

June 20, 2024

·

5 min read

Genetown

CENTOGENE Explores Strategic Alternatives

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders.

February 28, 2024

·

5 min read

Genetown

CENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionExpanding Relationship With Lifera, a Biopharma Company Owned by the PIF

Centogene N.V. announced it has entered into a set of agreements with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund in Saudi Arabia.

May 15, 2024

·

5 min read

Business

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.

May 15, 2024

·

19 min read

Press Releases

CENTOGENE Receives Delisting Notice From Nasdaq

August 8, 2024

·

5 min read

Genetown

CENTOGENE Receives French Research Tax Credit Accreditation

Centogene N.V. announced that it has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France.

January 24, 2024

·

4 min read

Genetown

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study , being conducted to advance the genetic understanding of frontotemporal dementia (FTD).

December 13, 2023

·

7 min read